Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

The NSCLC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Schrödinger, Inc. today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. "We are very proud of our accomplishments in 2024. We advanced ...

Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated ...

The rest of Plexxikon's pipeline is in early clinical or preclinical ... Pharmaphorum reached out to Daiichi Sankyo to ask for details about the fate of the programmes and Plexxikon's 60-strong ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

The agreement is one of a series of pipeline-boosting deals that MSD ... of three antibody-drug conjugate (ADC) therapies from Daiichi Sankyo for $4 billion upfront in October last year.